Supernus Pharmaceuticals (SUPN) Accounts Payables (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Accounts Payables data on file, last reported at $101.2 million in Q1 2026.

• On a quarterly basis, Accounts Payables rose 31.67% year-over-year to $101.2 million in Q1 2026; TTM through Mar 2026 was $101.2 million, a 31.67% increase from a year earlier, with the FY2025 full-year figure at $107.8 million, up 41.19% from the prior year.
• Accounts Payables for Q1 2026 stood at $101.2 million, down from $107.8 million in the prior quarter.
• Over the last five years, Accounts Payables for SUPN reached as high as $133.0 million in Q2 2022 and fell as low as $75.8 million in Q3 2024.
• Historically, Accounts Payables has averaged $91.7 million across 5 years, with a median of $86.4 million in 2024.
• Across the five-year window, Accounts Payables jumped 66.26% in 2022 and slumped 37.56% in 2023, its largest moves.
• Year by year, Accounts Payables stood at $96.3 million in 2022, then slipped by 17.41% to $79.6 million in 2023, then slipped by 4.04% to $76.4 million in 2024, then soared by 41.19% to $107.8 million in 2025, then decreased by 6.08% to $101.2 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $101.2 million in Q1 2026, $107.8 million in Q4 2025, and $108.6 million in Q3 2025.